Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Consolidated Statement of Operations Data:
Gain on derivatives resulting from change in fair value	$ 2,850,171	$ 1,597,372	$ 3,368,977	$ 2,263,756
Total other income, net	2,597,113us-gaap_NonoperatingIncomeExpense	1,595,131us-gaap_NonoperatingIncomeExpense	2,932,705us-gaap_NonoperatingIncomeExpense	1,511,692us-gaap_NonoperatingIncomeExpense
Net Income (Loss)	324,022us-gaap_NetIncomeLoss	(1,315,318)us-gaap_NetIncomeLoss	(4,705,227)us-gaap_NetIncomeLoss	(6,833,659)us-gaap_NetIncomeLoss
Earnings Per Share, Basic and Diluted, Total	$ 0.06us-gaap_EarningsPerShareBasicAndDiluted	$ (0.46)us-gaap_EarningsPerShareBasicAndDiluted	$ (1.31)us-gaap_EarningsPerShareBasicAndDiluted	$ (2.47)us-gaap_EarningsPerShareBasicAndDiluted
Scenario, Previously Reported [Member]
Consolidated Statement of Operations Data:
Gain on derivatives resulting from change in fair value	2,020,433		2,539,239
Total other income, net	1,767,375		2,102,967
Net Income (Loss)	(505,716)		(5,534,965)
Earnings Per Share, Basic and Diluted, Total	$ (0.10)		$ (1.54)
Restatement Adjustment [Member]
Consolidated Statement of Operations Data:
Gain on derivatives resulting from change in fair value	829,738		829,738
Total other income, net	829,738		829,738
Net Income (Loss)	$ 829,738		$ 829,738
Earnings Per Share, Basic and Diluted, Total	$ 0.17		$ 0.23

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.